Polyvalent Human Immunoglobulin for Infectious Diseases: Potential to Circumvent Antimicrobial Resistance

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jan 30

PMID 36713426

Authors

Sigifredo Pedraza-Sanchez

Adrian Cruz-Gonzalez

Oscar Palmeros-Rojas

Jose Luis Galvez-Romero

Joseph A Bellanti

Martha Torres

Affiliations

Soon will be listed here.

Abstract

Antimicrobial resistance (AMR) is a global health problem that causes more than 1.27 million deaths annually; therefore, it is urgent to focus efforts on solving or reducing this problem. The major causes of AMR are the misuse of antibiotics and antimicrobials in agriculture, veterinary medicine, and human medicine, which favors the selection of drug-resistant microbes. One of the strategies proposed to overcome the problem of AMR is to use polyvalent human immunoglobulin or IVIG. The main advantage of this classic form of passive immunization is its capacity to enhance natural immunity mechanisms to eliminate bacteria, viruses, or fungi safely and physiologically. Experimental data suggest that, for some infections, local administration of IVIG may produce better results with a lower dose than intravenous application. This review presents evidence supporting the use of polyvalent human immunoglobulin in AMR, and the potential and challenges associated with its proposed usage.

Citing Articles

Prenatal Inflammation Reprograms Hypothalamic-Pituitary-Gonadal Axis Development in Female Rats.

Ignatiuk V, Sharova V, Zakharova L Inflammation. 2025; .

PMID: 39909991 DOI: 10.1007/s10753-025-02243-2.

Efficacy of azithromycin combined with intravenous immunoglobulin in the treatment of refractory mycoplasma pneumoniae pneumonia in children: a meta-analysis.

Shen Y, Feng Z, Wang Z, Wang X, Luo C, Liu Q BMC Pediatr. 2024; 24(1):678.

PMID: 39455988 PMC: 11515308. DOI: 10.1186/s12887-024-05150-x.

References

Galeotti C, Kaveri S, Bayry J . IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol. 2017; 29(11):491-498. DOI: 10.1093/intimm/dxx039. View

Lachmann R, van Kaam A, Haitsma J, Verbrugge S, Delreu F, Lachmann B . Immunoglobulin M-enriched intravenous polyclonal immunoglobulins reduce bacteremia following Klebsiella pneumoniae infection in an acute respiratory distress syndrome rat model. Exp Lung Res. 2004; 30(4):251-60. DOI: 10.1080/01902140490439013. View

Ramisse F, Deramoudt F, Szatanik M, Bianchi A, Binder P, Hannoun C . Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab')2 fragments. Clin Exp Immunol. 1998; 111(3):583-7. PMC: 1904895. DOI: 10.1046/j.1365-2249.1998.00538.x. View

Farag N, Mahran L, Abou-Aisha K, El-Azizi M . Assessment of the efficacy of polyclonal intravenous immunoglobulin G (IVIG) against the infectivity of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo. Eur J Clin Microbiol Infect Dis. 2013; 32(9):1149-60. DOI: 10.1007/s10096-013-1861-5. View

Leung D, Kelly C, Boguniewicz M, Pothoulakis C, Lamont J, Flores A . Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr. 1991; 118(4 Pt 1):633-7. DOI: 10.1016/s0022-3476(05)83393-1. View

Murphy C, Vernon M, Cullen M . Intravenous immunoglobulin for resistant Clostridium difficile infection. Age Ageing. 2005; 35(1):85-6. DOI: 10.1093/ageing/afi212. View

Orange J, Grossman W, Navickis R, Wilkes M . Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol. 2010; 137(1):21-30. DOI: 10.1016/j.clim.2010.06.012. View

Arkilo D, Pierce B, Ritter F, Doescher J, Frost M . Diverse seizure presentation of acute Mycoplasma pneumoniae encephalitis resolving with immunotherapy. J Child Neurol. 2013; 29(4):564-6. DOI: 10.1177/0883073813480242. View

Bruss J, Siber G . Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model. Clin Diagn Lab Immunol. 1999; 6(4):464-70. PMC: 95709. DOI: 10.1128/CDLI.6.4.464-470.1999. View

10.

Wenjing L, Yuanzheng F, Li J, Tang L, Yu H . Safety and efficacy of convalescent plasma therapy in severely and critically ill patients with COVID-19: a systematic review with meta-analysis. Aging (Albany NY). 2020; 13(1):1498-1509. PMC: 7835046. DOI: 10.18632/aging.202195. View

11.

Lei J, Sun L, Huang S, Zhu C, Li P, He J . The antimicrobial peptides and their potential clinical applications. Am J Transl Res. 2019; 11(7):3919-3931. PMC: 6684887. View

12.

Katoh H, Yasumoto H, Shimizu M, Hamaoka S, Kinoshita M, Akiyama K . IV Immunoglobulin for Acute Lung Injury and Bacteremia in Pseudomonas aeruginosa Pneumonia. Crit Care Med. 2015; 44(1):e12-24. DOI: 10.1097/CCM.0000000000001271. View

13.

Gagliotti C, Balode A, Baquero F, Degener J, Grundmann H, Gur D . Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009. Euro Surveill. 2011; 16(11). DOI: 10.2807/ese.16.11.19819-en. View

14.

Basta M, Van Goor F, Luccioli S, Billings E, Vortmeyer A, Baranyi L . F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med. 2003; 9(4):431-8. DOI: 10.1038/nm836. View

15.

Gajdacs M . The Concept of an Ideal Antibiotic: Implications for Drug Design. Molecules. 2019; 24(5). PMC: 6429336. DOI: 10.3390/molecules24050892. View

16.

Sarker S, Sultana S, Reuteler G, Moine D, Descombes P, Charton F . Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh. EBioMedicine. 2016; 4:124-37. PMC: 4776075. DOI: 10.1016/j.ebiom.2015.12.023. View

17.

Bassetti M, Righi E, Carnelutti A, Graziano E, Russo A . Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control. Expert Rev Anti Infect Ther. 2018; 16(10):749-761. DOI: 10.1080/14787210.2018.1522249. View

18.

Hawser S, Bouchillon S, Lascols C, Hackel M, Hoban D, Badal R . Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009). Clin Microbiol Infect. 2011; 18(3):253-9. DOI: 10.1111/j.1469-0691.2011.03550.x. View

19.

Itoh H, Matsuo H, Kitamura N, Yamamoto S, Higuchi T, Takematsu H . Enhancement of neutrophil autophagy by an IVIG preparation against multidrug-resistant bacteria as well as drug-sensitive strains. J Leukoc Biol. 2015; 98(1):107-17. PMC: 4467167. DOI: 10.1189/jlb.4A0813-422RRR. View

20.

Norrby-Teglund A, Haque K, Hammarstrom L . Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med. 2006; 260(6):509-16. DOI: 10.1111/j.1365-2796.2006.01726.x. View